Peregrine Pharma expands CMO work while remaking R&D efforts

peregrine
Peregrine Pharmaceuticals headquarters

Tustin, CA-based Peregrine Pharmaceuticals ($PPHM) today touted its growth in contract manufacturing, saying a second facility has completed validation runs in preparation for commercial production and a third facility is being planned. The expansion of the contract manufacturing will help support the company as it reworks its R&D operations following the Phase III failure for its lead cancer drug, a pipeline project that had drawn interest from AstraZeneca, according to FierceBiotech.

Peregrine said today that Avid Bioservices, it contract manufacturing subsidiary, did $44 million in revenue for fiscal year 2016, up from $26.7 million in contract manufacturing the year before. It expects to grow that even further this year. Avid in March completed a 40,000-square-foot facility, located adjacent to the company's Tustin, CA, headquarters. That facility recently completed validation runs for three clients. The next step is to start commercial production at the facility.

"The past several months have been a busy and productive time at Peregrine as we work to optimally position the company for future success with both our contract manufacturing and drug development businesses,” CEO Steven W. King said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

While contract manufacturing is growing, the California company has struggled with its drug development. According to FierceBiotech, Peregrine reported in February that a combo of its lead drug bavituximab with docetaxel had failed a futility analysis comparing it with docetaxel alone. Now Peregrine will return to a series of small, early-stage combination studies with immunotherapy drugs.

Peregrine said today, “As part of these efforts, Peregrine is working closely with AstraZeneca to identify the optimal strategy for the companies’ clinical development collaboration focused on combining bavituximab with AstraZeneca’s PD-L1 inhibitor, durvalumab.  It is expected that the initial trial in the collaboration will be a Phase I study evaluating the treatment combination in a range of solid tumors.”

- here’s the release 
- read the FierceBiotech story

Related Article: 
Peregrine's Avid Bioservices unit wraps California biologics expansion

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.